• Ovarian Cancer

    • About CVac™

    • Treatment

    • Clinical Trials

Announcements23 January 2013
Quaterly Activity Report

QUARTERLY ACTIVITY REPORT
For Quarter ending 31 December 2012

Prima BioMed Ltd (Prima) (ASX: PRR; NASDAQ: PBMD; ISIN: US7415482034) released its Appendix 4C – Quarterly Report for the three month period ending 31 December 2012.
The cash balance at 31 December 2012 was A$ 28.07 million.
The majority of funds spent during the quarter are related to development activities of Prima’s lead product CVac.

Business highlights from the quarter:
• Transition of Ian Bangs as CFO and Company Secretary to Marc Voigt as CFO and Deanne Miller as Company Secretary.
• Positive interim CVac data from the ongoing CAN-003 trial.
• Positive interim immune monitoring data from ongoing CAN-003 trial.
• Annual General Meeting at 16th of Nov 2012.

For more details about these highlights and Prima’s activities, please refer to Prima’s
announcements on the ASX website.

ml>
distributed by